secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2023-12-28T23:59:59+00:00
Accession:  0001193125-23-305187
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics terminates CEO Kevin S. Boyle; separation payment ~$331,990 plus consulting deal
--------------------------------------------------------------------------------

- CEO Kevin S. Boyle terminated effective Dec 22, 2023; separation payment ~$331,990 (six months base salary + COBRA).
- Mr. Boyle also executed a mutual release and resigned from board of directors.
- Consulting agreement from Jan 1, 2024, for six months at $15,000/month for strategic advisory.
- No successor or interim CEO announced; transition details limited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/d473634d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-305187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer